A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
Novo Nordisk Pharma disclosed on its website on November 16 that it will discontinue all three subcutaneous single-dose versions of its GLP-1 receptor agonist Ozempic (semaglutide), a treatment for type 2 diabetes. Ozempic is available as three single-dose devices (0.25…
To read the full story
Related Article
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
August 8, 2023
- Trulicity, Rybelsus Might Gain Ground in GLP-1 Market amid Ozempic Supply Woes
March 2, 2022
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
- Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
February 22, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
BUSINESS
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
- Astellas to Offload Seroquel, “G1” LLP, to LTL Pharma
January 17, 2025
- J-TEC, Kobe Cell Therapy Player Form Capital Alliance
January 16, 2025
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- AnGes Partners with Stanford on Cancer Therapy Research
January 16, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…